- ISIN
- US89853L1044
- CUSIP
- 89853L104
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Aug 7, 2014
Highlights
- Total Revenue (TTM)
- $7.68M
- Gross Profit (TTM)
- -$5.97M
- EBITDA (TTM)
- -$39.51M
- Year Range
- $0.00 - $0.16
- Target Price
- $5.00
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TTOO Performance Chart
T2 Biosystems, Inc. (TTOO) is down 60.0% since the beginning of the year. At $0 per share, TTOO is trading 98.8% below its 52-week high of $0. Investors who bought $1,000 worth of TTOO shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Returns By Period
T2 Biosystems, Inc. (TTOO) has returned -60.00% so far this year and -98.76% over the past 12 months. Over the last ten years, TTOO has returned -81.65% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.
T2 Biosystems, Inc.
- 1D
- 0.00%
- 1M
- -33.33%
- YTD
- -60.00%
- 6M
- -81.82%
- 1Y
- -98.76%
- 3Y*
- -94.19%
- 5Y*
- -94.95%
- 10Y*
- -81.65%
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
TTOO Monthly Returns History
Based on dividend-adjusted daily data since Aug 7, 2014, TTOO's average daily return is +1.34%, while the average monthly return is +3.57%. At this rate, an investment would double in approximately 1.6 years.
Historically, 35% of months were positive and 65% were negative. The best month was Apr 2026 with a return of +900.0%, while the worst month was Jul 2025 at -87.1%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 10 months.
On a daily basis, TTOO closed higher 41% of trading days. The best single day was Apr 15, 2026 with a return of +900.0%, while the worst single day was Apr 17, 2026 at -90.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -56.00% | 0.00% | -86.36% | 900.00% | -86.67% | 400.00% | -60.00% | ||||||
| 2025 | -48.81% | -41.86% | -1.60% | -6.50% | 40.00% | -13.60% | -87.06% | -77.78% | 210.00% | -11.29% | 10.00% | -58.68% | -98.81% |
| 2024 | -28.29% | 12.00% | -40.48% | 11.83% | 53.20% | 3.89% | -8.61% | -34.63% | -38.24% | -55.54% | -34.70% | -26.57% | -93.31% |
| 2023 | 10.56% | -60.83% | -25.20% | -28.26% | -72.73% | -21.56% | 108.92% | 112.20% | -29.42% | -73.25% | -40.10% | 77.26% | -95.58% |
| 2022 | -18.64% | 3.60% | 20.46% | -29.40% | -45.30% | -20.21% | -25.33% | 1.58% | -7.76% | -67.26% | -10.27% | -14.46% | -94.50% |
| 2021 | 60.48% | 15.08% | -29.26% | -14.81% | 0.72% | -14.39% | -13.45% | -9.27% | -2.07% | -15.37% | -19.97% | -16.72% | -58.37% |
Benchmark Metrics
T2 Biosystems, Inc. has an annualized alpha of 2493.37%, beta of 0.78, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since August 08, 2014.
- This stock participated in 249.20% of S&P 500 Index downside but only -135.90% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 2,493.37%
- Beta
- 0.78
- R²
- 0.00
- Upside Capture
- -135.90%
- Downside Capture
- 249.20%
Return for Risk
Risk / Return Rank
TTOO ranks 51 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for T2 Biosystems, Inc. (TTOO) and compare them to S&P 500 Index.
| TTOO | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.06 | 2.39 | -2.45 |
Sortino ratioReturn per unit of downside risk | 11.90 | 3.25 | +8.64 |
Omega ratioGain probability vs. loss probability | 2.89 | 1.43 | +1.45 |
Calmar ratioReturn relative to maximum drawdown | -0.99 | 3.11 | -4.10 |
Martin ratioReturn relative to average drawdown | -1.11 | 14.38 | -15.49 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the T2 Biosystems, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the T2 Biosystems, Inc. was 100.00%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current T2 Biosystems, Inc. drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -100.00%Mar 2026 | 11y 2mo | — | 11y 4moJan 2015 - now |
2014 bear market2014 | -40.24%Oct 2014 | 1mo 20d | 2mo 24d | 4mo 14dSep 2014 - Jan 2015 |
2014 correction2014 | -11.06%Aug 2014 | 0s | 8d | 8dAug 2014 - Aug 2014 |
2014 pullback2014 | -6.42%Aug 2014 | 0s | 4d | 4dAug 2014 - Aug 2014 |
2014 pullback2014 | -1.68%Aug 2014 | 0s | 3d | 3dAug 2014 - Aug 2014 |
Drawdown Indicators
| TTOO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -99.88% | -9.10% | -90.78% |
Max Drawdown (3Y)Largest decline over 3 years | -100.00% | -18.90% | -81.10% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -25.43% | -74.57% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -33.92% | -66.08% |
Current DrawdownCurrent decline from peak | -100.00% | 0.00% | -100.00% |
Average DrawdownAverage peak-to-trough decline | -83.65% | -10.72% | -72.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 88.91% | 1.97% | +86.94% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of T2 Biosystems, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how T2 Biosystems, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TTOO
Add T2 Biosystems, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TTOO